Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials
Badran AS, Helal A, Shata KS, et al. Obesity Research & Clinical Practice 2026;20:2-12.
What it found
Across five randomised trials, tesamorelin lowered visceral fat (mean difference -27.7 cm²), trunk fat, liver fat and waist size, and raised lean body mass. Subcutaneous fat and BMI did not fall significantly, and CD4 counts did not change. Reported side effects included joint pain, muscle pain, tingling and injection-site redness.
Limitations
Based on only five trials, all in people with HIV; several share the same research groups.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.